[Possibilities and limitations of selective beta 1 adrenergic receptor blockade in clinical practice].
The use of various doses of metoprolol (spesicor, Leiras, Finland), a selective beta 1-adrenoblocker, in patients with CHD combined with clinical or instrumentally detectable symptoms of bronchial asthma or stage I-II essential hypertension with angina pectoris of I-II functional classes, has shown that metoprolol cardioselective blockade is a relative phenomenon which has definite correlation with a dose, duration of therapy, and the initial status of the bronchopulmonary system. An antianginal effect was observed in 68.5% of patients, an antihypertensive effect--in 71.3%, side-effects--in 6.4%.